Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: This study evaluated change in health‐related quality of life (HRQOL) associated with ongoing weight change among patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin, a highly selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion and is associated with body weight reductions. Methods: Patients with T2DM who had inadequate glycaemic control on metformin (MET) alone were enrolled in a 24‐week, double‐blind, randomized, placebo‐controlled study with a 78‐week extension to evaluate the effect of dapagliflozin + MET on body weight. Patients also completed the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes Weight Questionnaire‐9 (SHIELD‐WQ‐9), a weight change‐related HRQOL survey. Difference in proportions of patients treated with dapagliflozin 10 mg + MET (n = 89) or placebo + MET (n = 91) who reported improvement in HRQOL was analysed with Fisher's exact test. Results: Dapagliflozin patients had significantly greater weight loss than placebo patients over 102 weeks (p < 0.05). This corresponded to a numerically greater proportion of dapagliflozin‐treated patients reporting ongoing weight loss and associated improvements in most HRQOL domains at three different evaluation points (weeks 24, 50 and 102) than placebo‐treated patients. In a post‐hoc analysis among patients who reported ongoing weight loss regardless of treatment arm, a significantly greater proportion of patients reporting weight loss versus weight gain reported improvements in physical health, self‐esteem and overall HRQOL at weeks 24, 50 and 102. Conclusions: Dapagliflozin‐induced weight loss was associated with improvement in overall HRQOL. Overall, ongoing weight loss was associated with improvements in several HRQOL domains compared with weight gain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 3×
“In a recent 24-week, international, doubleblind, randomized, placebo-controlled study, dapagliflozin reduced total body weight, predominantly by reducing fat mass, including visceral as well as subcutaneous adipose tissue, in patients with T2DM inadequately controlled with metformin [4].”
BackgroundSelf-citationThe Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Medication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Jha, A. K., Aubert, R. E., Yao, J., Teagarden, J. R., & Epstein, R. S. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1198 · Cited by 174
The 'cost' of medication nonadherence: Consequences we cannot afford to accept
Chisholm-Burns, M. A., & Spivey, C. A. (2012) · Journal of the American Pharmacists Association · doi:10.1331/japha.2012.11088 · Cited by 173 · cited 1×
“It has been shown that medication non-adherence results in increased healthcare costs as well as worsening diabetes [13].”
Background
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“Hence, prioritizing metformin, incretin-based medications, and SGLT-2s as therapeutic strategies can reduce exercise-related hypoglycemia and potentially increase the safety and efficacy of exercise in patients with diabetes, thus supporting this important weight-reduction strategy (67, 68).”
BackgroundScheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[70] Such dapagliflozin-induced weight loss was associated with improvement in overall healthrelated quality of life.[71]”
BackgroundStrategies to reduce attrition in weight loss interventions: A systematic review and meta‐analysis
Pirotta, S., Joham, A., Hochberg, L., Moran, L., Lim, S., Hindle, A., & Brennan, L. (2019) · Obesity Reviews · doi:10.1111/obr.12914 · Cited by 45
“The majority of trials were conducted in North America(28-71) with only one being multinational.(72,73) Thirteen studies had a female‐only cohort,(30,31,34,36,37,40,45,50,61,71,74-77) seven investigated strategies within young adults (≤35 y),(30,52,66,74,75,78-80) and three had a sample size greater than 500.”
Background
Metadata
- Authors
- Grandy, S., Hashemi, M., Langkilde, A. ‐., Parikh, S., & Sjöström, C. D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-02-09
- Volume
- 16
- Issue
- 7
- Pages
- 645-650
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1925323738
- Cited by
- 44
- References
- 5
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. https://app.cochat.ai/papers/10.1111/dom.12263
- The paper
- Grandy, S., Hashemi, M., Langkilde, A. ‐., Parikh, S., & Sjöström, C. D. (2014). Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.